Sapient Capital’s Intensity Therapeutics INTS Stock Holding History

Sapient Capital’s Portfolio INTS Stock Details INTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Hold	26,006	–	–	﹤0.01%	390
2026 Q1	$153K	Hold	26,006	–	–	﹤0.01%	433
2025 Q4	$244K	Sell	26,006 -13,066	-33%	-$132K	﹤0.01%	377
2025 Q3	$240K	Hold	39,072	–	–	﹤0.01%	351
2025 Q2	$300K	Hold	39,072	–	–	0.01%	305
2025 Q1	$1.92M	Buy	39,072 +1,358	+4%	+$75.5K	0.04%	148
2024 Q4	$1.66M	Sell	37,714 -2,716	-7%	-$197K	0.03%	155
2024 Q3	$3.86M	Hold	40,430	–	–	0.08%	102
2024 Q2	$4.95M	Sell	40,430 -53	-0.1%	-$6.01K	0.1%	93
2024 Q1	$5.26M	Buy	40,483 +32,483	+406%	+$3.89M	0.12%	99
2023 Q4	$1.71M	Buy	+8,000	New	+$842K	0.04%	132

Other funds holding INTS

KWM

KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Mercer Global Advisors Denver, Colorado $80B AUM 26.12% 1-Year Est. Return

Sapient Capital's INTS Position: Q2 2026 in Review

Sapient Capital held its Intensity Therapeutics (INTS) position steady in Q2 2026 at 26,006 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #390.

Sapient Capital first reported a position in INTS in Q4 2023 and has held it in 11 quarters since. The position peaked at $5.26M in Q1 2024. 14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

Sapient Capital held 26,006 shares of Intensity Therapeutics worth $107K as of Q2 2026.
Sapient Capital left its Intensity Therapeutics share count unchanged in Q2 2026.
Intensity Therapeutics made up ﹤0.01% of Sapient Capital's portfolio in Q2 2026, its #390 holding.
Sapient Capital first reported a position in Intensity Therapeutics in Q4 2023 and has held it in 11 quarters since.
Sapient Capital's Intensity Therapeutics position peaked at $5.26M in Q1 2024.
14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.